Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis

Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies

“…The safety and efficacy of both products have been demonstrated in short-term and long-term studies for up to 1 year. [1][2][3][4][5][6][7][8][9][10][11][12] Additional long-term studies have been conducted with tacrolimus ointment 0.1% and demonstrated no safety concerns in patients treated for up to 4 years. 13 From a clinical perspective, the effectiveness of treatments for AD is evaluated on the basis of the rate with which patients respond to the therapy, the magnitude of the response, the decrease in the area affected, and the patient's subjective response, particularly the decrease in extent of itch.…”

“…13 From a clinical perspective, the effectiveness of treatments for AD is evaluated on the basis of the rate with which patients respond to the therapy, the magnitude of the response, the decrease in the area affected, and the patient's subjective response, particularly the decrease in extent of itch. Results from independently conducted studies 9,10 suggest that tacrolimus ointment may be more effective than pimecrolimus cream in the treatment of AD, but no adequate, well-controlled studies comparing the efficacy of topical tacrolimus and pimecrolimus have been published. Kempers et al 14 recently published a randomized, investigator-blinded study comparing tacrolimus ointment to pimecrolimus cream in pediatric patients with moderate AD.…”

Comparative Effect of Tacrolimus and Betamethasone Valerate on the Passive Sustainable Hydration of the Stratum Corneum in Atopic Dermatitis

“…For many years, topical corticosteroid therapy remained the standard of care [36, 37] but the new topical calcineurin inhibitors have opened a new pharmacological era in this field [1, 2,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20]. The effect of theses drugs on the functional properties of atopic skin have not been thoroughly explored so far.…”

“…Moderate to severe refractory atopic dermatitis is the major indication of topical tacrolimus [6,7,8,9,10,11,12,13,14,15,16,17,18,19,20]. In this condition, the primary target is the inflammatory cells including the T lymphocytes and Langerhans cells.…”

The efficacy and safety of tacrolimus ointment: A clinical review

“…Although the above long-term studies focused on patients with moderate to severe disease, Chapman et al 19 report the efficacy and safety of tacrolimus ointment for the treatment of mild to moderate AD in both children and adults. In these 6-week, double-blind, randomized vehicle-controlled studies, tacrolimus 0.03% ointment demonstrated superior efficacy over vehicle.…”